For the complete report, get in touch with us at : info@netscribes.com Cardiovascular pharmaceuticals market in India is the second largest contributor to domestic pharmaceutical sales, contributing around 15.6%. Since India has a huge patient pool, the Indian market is characterized by a huge demand for cardiovascular drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, patent expiry of popular blockbuster drugs, increase in disposable income and introduction of newer and better drugs is helping the market to grow. The Indian Government, on its part has taken initiatives to reduce drug prices, has made certain reforms in the tax structure and has undertaken various control programmes. The market is expected to exhibit steady growth over the next few years. The report begins with the introduction section which offers a brief insight into the major cardiovascular drug classes. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth. An analysis of the drivers explains the factors for growth of the industry including increasing patient population, patent expiry of blockbuster drugs, increase in disposable income and introduction of newer and better drugs. The key challenges include strong competition between the different pharma companies and competition from complementary and alternative medicines. The government initiatives section gives analyses the efforts to reduce drug prices, changes in the customs duty structure and the various control programmes undertaken by the Government. A brief overview of the drug market value chain, drug regulations and patents is presented in the next section. It analyses the pharmaceutical value chain, and focuses on the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. A snapshot of different regulatory frameworks existing in the Indian pharma industry have been shown. The section also provides a list of important patent approvals for cardiovascular drugs.

1. Insert Cover Image using Slide Master View
Do not distort
Cardiovascular Pharmaceuticals Market - India
September 2011

2. Executive Summary
Cardiovascular pharmaceuticals market in India is valued at INR X bn in 20--
Market The market is expected to grow at a CAGR of y% from 20-----
CVD segment is the second largest contributor to domestic sales, contributing around x %
Drivers: Challenges:
Increasing patient base Strong competition
Drivers and
Patent expiry of blockbuster drugs Competition from complementary and
Challenges
Increasing disposable income
Introduction of new drugs
Drug value chain
PLE alternative medicines
Drug regulation
and patents
Government
Phases of clinical trial
SAM
Approval and licensing of drugs
Patent approvals
Reduction in drug prices
Changes in tax structure
initiatives Control Programmes
Highly fragmented market with large number of players
Major foreign players in the market include Company 1, Company 2, Company 3 etc
Competition
Major domestic companies include Company 4, Company 5, Company 6 among others
CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT 2

3. •Introduction
•Market Overview
•Drivers & Challenges
•Government Initiatives
•Market Value Chain, Regulation and
Patents
•Competition
•Strategic recommendation
CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT 3

4. Indian cardiovascular pharma market is expected to witness
huge growth in the coming years
Indian Market – Overview Market Size and Growth
• Cardiovascular therapeutic segment belongs to the INR bn
chronic segment (comprising of cardiovascular, anti 150
x6
diabetics and neuro pshychiatry), which together y%
x5
account for around A% of the total pharma market 100 x4
x3
x2
• Cardiovascular segment is the second largest x1
50
contributor to domestic pharmaceuticals market
sales, with a share of x% 0
2010 2011e 2012e 2013e 2014e 2015e
Within the cardiovascular segment, antihypertensive drugs
account for almost m% of revenue
• Presently the market has a size of INR X bn and is LE
Cholesterol lowering drugs account for one third of sales
P
Top Pharmaceutical Segments – 20--
0 2 4 6 8 10 12 14 16 18
expected to grow at a CAGR of y% from 20-- to 20--
to reach INR Y bn
• Annually, B million Indians die of cardiovascular
diseases SAM anti-infectives
CVD
gastro
CNS
respiratory
diabetes
pain
Y5
Y6
y7
Y4
Y3
Y2
Y%
1
gynaecology Y8
• According to WHO estimates, by 2020, almost a% of urology y9
oncology Y 10
cardiac patients worldwide will be Indian
Source:
CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT 4

5. Drivers & Challenges - Summary
Drivers Challenges
Increasing patient base Strong competition
Patent expiry of blockbuster drugs Competition from complementary and
alternative medicines
Increasing disposable income
Introduction of new drugs
CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT 5

6. Government Initiatives – Summary
Reduction in drug prices
Government
Initiatives
Control programs Changes in tax structure
CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT 6

7. Major domestic players in the market (1/9)
Company Snapshot: Company 1
Corporate Information Financial Performance
Revenue Revenue Profit
Headquarters City 1, State 1
INR bn INR bn
Profit / Loss
Founded 19-- 100 r4 60
r2 r3
r1
40
Products Product 1, Product 2
50
20
E
Key People Person X– MD
L
0 0
P
2008 2009 2010 2011
Business Highlights
SAM
• Employing around n people, Company 1 is India’s largest pharmaceutical company, having manufacturing facilities in
m countries and serving customers in over n countries
• In 20--, the company received the USFDA approval to manufacture and market cardiovascular drug Product Y
• In 20--, the company entered into an alliance with Company X, one of the largest Japanese innovator companies to
create an innovator and generic pharmaceuticals powerhouse
• In 20--, Company 1 entered into an in licensing agreement with Company Y, for the marketing of a fixed dose
combination of Product A and Product B, under the brand name Product C
Source:
CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT 7

8. Thank you for the attention
The Cardiovascular Pharmaceuticals Market – India report is part of Netscribes’ Healthcare
Industry Series.
For more detailed information or customized research requirements please contact:
Tamojit Roy Gagan Uppal
Phone: +91 33 4064 6215 Phone: +91 22 4098 7530
E-Mail: tamojit.roy@netscribes.com E-Mail: gagan.uppal@netscribes.com
Research on India is a product of Netscribes (India) Pvt. Ltd. Research on India is dedicated to disseminating information and providing quick
insights on “hot” industries in India and other emerging markets. Track our new releases and major updates in these industries on
About Netscribes
Netscribes is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &
business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true
value proposition that draws upon a vast knowledge base. Netscribes is a one-stop shop designed to fulfil clients’ profitability and growth
objectives.
Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Research on India,
Netscribes (India) Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the
sole property of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction.
CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT 8